{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T17:21:08Z","timestamp":1759339268631,"version":"3.44.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005035","name":"Biotronik","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.ijcard.2019.05.071","type":"journal-article","created":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T22:36:40Z","timestamp":1559255800000},"page":"260-265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Number of drugs used in secondary cardiovascular prevention and late survival in the population of Valencia Community, Spain"],"prefix":"10.1016","volume":"293","author":[{"given":"Josep","family":"Red\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Us\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"Trillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Morales-Olivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Sanch\u00eds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domingo","family":"Orozco-Beltr\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2019.05.071_bb0005","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/hrt.2009.188607","article-title":"The effect of optimal medical therapy on 1-year mortality after acute myocardial infarction","volume":"96","author":"Bramlage","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2019.05.071_bb0010","first-page":"247","article-title":"Adherence to evidence-based therapies after acute coronary syndrome: a retrospective population-based cohort study linking hospital, outpatient, and pharmacy health information systems in Valencia, Spain","volume":"19","author":"Sanf\u00e9lix-Gimeno","year":"2013","journal-title":"J. Manag. Care Pharm."},{"key":"10.1016\/j.ijcard.2019.05.071_bb0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.recesp.2010.07.005","article-title":"Randomized clinical trial to assess the efficacy of a comprehensive programme of secondary prevention of cardiovascular disease in general practice: the PREseAP study","volume":"64","author":"Brotons","year":"2011","journal-title":"Rev. Esp. Cardiol."},{"key":"10.1016\/j.ijcard.2019.05.071_bb0020","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"Perk","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2019.05.071_bb0025","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMra1606915","article-title":"Acute myocardial infarction","volume":"376","author":"Anderson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2019.05.071_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2017.04.052","article-title":"Global, regional and national burden of cardiovascular diseases for 10 causes: 1990 to 2015","volume":"70","author":"Roth","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2019.05.071_bb0035","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2019.05.071_bb0040","first-page":"1559e66","article-title":"Reduction of in-hospital mortality and improved secondary prevention after acute myocardial infarction. First results from the registry of secondary prevention after acute myocardial infarction (SAMI)","volume":"132","author":"Tebbe","year":"2007","journal-title":"Dtsch. Med. Wochenschr."},{"issue":"Supl 2","key":"10.1016\/j.ijcard.2019.05.071_bb0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.recesp.2011.02.027","article-title":"Compuestos de dosis fija en la prevenci\u00f3n secundaria de la cardiopat\u00eda isqu\u00e9mica","volume":"64","author":"Fuster","year":"2011","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.ijcard.2019.05.071_bb0050","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.amjcard.2011.01.013","article-title":"Adherence to statin therapy in elderly patients after hospitalization for coronary revascularization","volume":"107","author":"Kulik","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2019.05.071_bb0055","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/HJR.0b013e3283294b1d","article-title":"EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries","volume":"16","author":"Kotseva","year":"2009","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1016\/j.ijcard.2019.05.071_bb0060","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1503\/cmaj.080295","article-title":"Factors associated with the use of evidence-based therapies after discharge among elderly patients with myocardial infarction","volume":"179","author":"Austin","year":"2008","journal-title":"CMAJ"},{"key":"10.1016\/j.ijcard.2019.05.071_bb0065","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/pds.1671","article-title":"Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients","volume":"17","author":"Choudhry","year":"2008","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.ijcard.2019.05.071_bb0070","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","article-title":"Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences","volume":"34","author":"Chowdhury","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2019.05.071_bb0075","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1157\/13092980","article-title":"The secondary prevention of ischaemic heart disease in Spain. A systematic review of observational studies","volume":"38","author":"Sanf\u00e9lix","year":"2006","journal-title":"Aten. Primaria"},{"key":"10.1016\/j.ijcard.2019.05.071_bb0080","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ahj.2013.09.014","article-title":"Untangling the relationship between medication adherence and post-myocardial infarction outcomes: medication adherence and clinical outcomes","volume":"167","author":"Choudhry","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2019.05.071_bb0085","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.2174\/1381612820666140620162629","article-title":"Statin treatment non-adherence and discontinuation: clinical implications and potential solutions","volume":"20","author":"Phan","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ijcard.2019.05.071_bb0090","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1742-1241.2007.01683.x","article-title":"The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review","volume":"62","author":"Muszbek","year":"2008","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.ijcard.2019.05.071_bb0095","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.jacc.2014.08.021","article-title":"A polypill strategy to improve adherence: results from the FOCUS project","volume":"64","author":"Castellano","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2019.05.071_bb0100","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1001\/jama.2014.13616","article-title":"Fixed-dose combination therapy (polypill) for the prevention of cardiovascular disease","volume":"312","author":"Huffman","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2019.05.071_bb0105","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jacc.2013.08.1665","article-title":"Polypills: essential medicines for cardiovascular disease secondary prevention?","volume":"63","author":"Huffman","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2019.05.071_bb0110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ncpcardio1419","article-title":"Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population","volume":"6","author":"Sanz","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.ijcard.2019.05.071_bb0115","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.amjmed.2011.12.013","article-title":"Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients","volume":"125","author":"Naderi","year":"2012","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ijcard.2019.05.071_bb0120","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jacc.2016.06.005","article-title":"Assessing the impact of medication adherence on long-term cardiovascular outcomes","volume":"68","author":"Bansilal","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2019.05.071_bb0125","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/VHRM.S119490","article-title":"High adherence to therapy and low cardiac mortality and morbidity in patients after acute coronary syndrome systematically managed by office-based cardiologists in Germany: 1-year outcomes of the ProAcor Study","volume":"13","author":"Goss","year":"2017","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.ijcard.2019.05.071_bb0130","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/pds.3840","article-title":"Effect of adherence to evidence-based therapy after acute myocardial infarction on all-cause mortality","volume":"24","author":"Hamood","year":"2015","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.ijcard.2019.05.071_bb0135","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1177\/2047487315597209","article-title":"Determinants of adherence to evidence-based therapy after acute myocardial infarction","volume":"23","author":"Hamood","year":"2016","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.ijcard.2019.05.071_bb0140","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40263-017-0420-5","article-title":"Statin adherence and the risk of stroke: a dose-response meta-analysis","volume":"31","author":"Xu","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ijcard.2019.05.071_bb0145","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMc1010028","article-title":"Electronic health records","volume":"363","author":"Rodkey","year":"2010","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ijcard.2019.05.071_bb0150","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1001\/jama.2013.4638","article-title":"Medication nonadherence: a diagnosable and treatable medical condition","volume":"309","author":"Marcum","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2019.05.071_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189339","article-title":"Does cognitive impairment impact adherence? A systematic review and meta-analysis of the association between cognitive impairment and medication non-adherence in stroke","volume":"12","author":"Rohde","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ijcard.2019.05.071_bb0160","article-title":"Interventions to improve adherence to lipid-lowering medication","volume":"12","author":"van Driel","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ijcard.2019.05.071_bb0165","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jacc.2014.06.009","article-title":"A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality","volume":"64","author":"Castellano","year":"2014","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527319301135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527319301135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:44:51Z","timestamp":1759092291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527319301135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":33,"alternative-id":["S0167527319301135"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2019.05.071","relation":{},"ISSN":["0167-5273"],"issn-type":[{"type":"print","value":"0167-5273"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Number of drugs used in secondary cardiovascular prevention and late survival in the population of Valencia Community, Spain","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2019.05.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}